Please use this identifier to cite or link to this item:
Title: Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Epworth Authors: Prince, Miles
Other Authors: Gao, Crystal
McCormack, Christopher
van der Weyden, Carrie
Goh, Michelle
Campbell, Belinda
Twigger, Robert
Buelens, Odette
Harrison, Simon
Khoo, Christine
Lade, Stephen
Keywords: Extracorporeal Photopheresis (ECP)
Sézary Syndrome (SS)
Erythrodermic Mycosis Fungoides (e-MF)
Novel Therapies
Retrospective Analysis
Overall Survival (OS)
Time to Next Treatment (TTNT),
Skin Response Rate (RR)
Histone Deacetylase Inhibitors
Novel Immunotherapy Agents
Low-Dose Methotrexate
Prolonged Survival
Systemic Agents
Autologous Stem Cell Transplant
Allogeneic Stem Cell Transplant
Synergistic Effect
Fusion Toxins
Antibody-Drug Conjugates
Monoclonal Antibodies
IV/Oral Chemotherapy
Epworth Centre for Immunotherapies and Snowdome Laboratories
Molecular Oncology and Cancer Immunology
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2019
Publisher: American Society of Hematology (ASH)
Citation: Blood, 134(16), 1346–1350.
Abstract: Extracorporeal photopheresis (ECP) has demonstrated therapeutic benefit in patients with Sézary syndrome (SS) and erythrodermic mycosis fungoides (e-MF). To examine the efficacy of ECP in the modern era of novel therapies, we conducted a retrospective analysis of 65 patients with a diagnosis of SS or e-MF with blood involvement who were treated with ECP at our institute. Overall survival (OS), time to next treatment (TTNT), and skin response rate (RR) were used as the study end points to determine patient outcome. The median follow-up from diagnosis was 48 months (range 1-225 months), with a median predicted OS of 120 months. The majority (88%) of patients commenced ECP at treatment lines 1 to 3, either as a monotherapy or in conjunction with other systemic agents. The use of ECP monotherapy resulted in a significantly longer median TTNT when compared with interferon-α (P = .0067), histone deacetylase inhibitors (P = .0003), novel immunotherapy agents (P = .028), low-dose methotrexate (P < .0001), and chemotherapy (P < .0001). In particular, early commencement of ECP at treatment lines 1 to 3 yielded a TTNT of 47 months. The results of our study support the utilization of ECP for SS/e-MF, and we recommend that ECP should be considered as early as possible in the treatment paradigm for these patients.
DOI: 10.1182/blood.2019000765
PubMed URL:
ISSN: 0006-4971
Journal Title: Blood
Type: Journal Article
Affiliated Organisations: Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, Australia
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Dermatology, St Vincent's Hospital, Melbourne, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
Type of Clinical Study or Trial: Retrospective studies
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.